These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30190974)

  • 21. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma.
    Lance C; McLennan G; Obuchowski N; Cheah G; Levitin A; Sands M; Spain J; Srinivas S; Shrikanthan S; Aucejo FN; Kim R; Menon KV
    J Vasc Interv Radiol; 2011 Dec; 22(12):1697-705. PubMed ID: 21983055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma.
    Kooby DA; Egnatashvili V; Srinivasan S; Chamsuddin A; Delman KA; Kauh J; Staley CA; Kim HS
    J Vasc Interv Radiol; 2010 Feb; 21(2):224-30. PubMed ID: 20022765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
    J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma.
    Nabrinsky E; James E
    Cureus; 2020 May; 12(5):e8163. PubMed ID: 32550079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients.
    Saxena A; Meteling B; Kapoor J; Golani S; Danta M; Morris DL; Bester L
    Int J Surg; 2014 Dec; 12(12):1403-8. PubMed ID: 25091398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
    Padia SA; Kwan SW; Roudsari B; Monsky WL; Coveler A; Harris WP
    J Vasc Interv Radiol; 2014 Jul; 25(7):1067-73. PubMed ID: 24837982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (90)Y-glass microspheres for hepatic neoplasia.
    Mahnken AH
    Future Oncol; 2015; 11(9):1343-54. PubMed ID: 25952780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.
    Zhan C; Ruohoniemi D; Shanbhogue KP; Wei J; Welling TH; Gu P; Park JS; Dagher NN; Taslakian B; Hickey RM
    J Vasc Interv Radiol; 2020 Jan; 31(1):25-34. PubMed ID: 31422022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.
    Kwok PC; Leung KC; Cheung MT; Lam TW; Szeto LT; Chou SQ; Chia NH; Tong CM; Yuen PK; Cheung CH; Law CK
    J Gastroenterol Hepatol; 2014 Nov; 29(11):1897-904. PubMed ID: 24734957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioembolization for the treatment of hepatocellular carcinoma.
    Kim HC
    Clin Mol Hepatol; 2017 Jun; 23(2):109-114. PubMed ID: 28494530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma.
    Chan LS; Sze DY; Poultsides GA; Louie JD; Abdelrazek Mohammed MA; Wang DS
    Cardiovasc Intervent Radiol; 2017 Sep; 40(9):1383-1391. PubMed ID: 28432387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness.
    Xing M; Kokabi N; Camacho JC; Kooby DA; El-Rayes BF; Kim HS
    J Comp Eff Res; 2013 Jul; 2(4):435-44. PubMed ID: 24236684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioembolization With Yttrium-90 Resin Microspheres in Hepatocellular Carcinoma: A Multicenter Prospective Study.
    Kim DY; Park BJ; Kim YH; Han KH; Cho SB; Cho KR; Uhm SH; Choe JG; Choi JY; Chun HJ; Lee HC; Gwon DI; Lee KH; Yoon JH; Chung JW; Kim CW; Heo J; Kim JK; Joo YE
    Am J Clin Oncol; 2015 Oct; 38(5):495-501. PubMed ID: 24064753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
    Vente MA; Wondergem M; van der Tweel I; van den Bosch MA; Zonnenberg BA; Lam MG; van Het Schip AD; Nijsen JF
    Eur Radiol; 2009 Apr; 19(4):951-9. PubMed ID: 18989675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma.
    D'Avola D; Lñarrairaegui M; Bilbao JI; Martinez-Cuesta A; Alegre F; Herrero JI; Quiroga J; Prieto J; Sangro B
    Hepatogastroenterology; 2009; 56(96):1683-8. PubMed ID: 20214218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres.
    Li MD; Chu KF; DePietro A; Wu V; Wehrenberg-Klee E; Zurkiya O; Liu RW; Ganguli S
    J Vasc Interv Radiol; 2019 Mar; 30(3):314-319. PubMed ID: 30819470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Yttrium-90 microsphere radioembolization for hepatocellular carcinoma.
    Edeline J; Gilabert M; Garin E; Boucher E; Raoul JL
    Liver Cancer; 2015 Mar; 4(1):16-25. PubMed ID: 26020026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
    Ricke J; Bulla K; Kolligs F; Peck-Radosavljevic M; Reimer P; Sangro B; Schott E; Schütte K; Verslype C; Walecki J; Malfertheiner P;
    Liver Int; 2015 Feb; 35(2):620-6. PubMed ID: 24930619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis.
    Jia Z; Jiang G; Tian F; Zhu C; Qin X
    Saudi J Gastroenterol; 2016; 22(5):353-359. PubMed ID: 27748320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.